Intra-Cellular Therapies, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Biotech Innovators

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Intra-Cellular Therapies, Inc. and CRISPR Therapeutics AG, two pioneers in the field, have shown contrasting approaches over the past decade.

From 2014 to 2023, Intra-Cellular Therapies, Inc. saw a staggering 3,865% increase in SG&A expenses, peaking at $410 million in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, CRISPR Therapeutics AG maintained a more conservative growth, with a 1,389% increase, reaching $76 million in 2023.

While Intra-Cellular Therapies, Inc. has invested heavily in scaling operations, CRISPR Therapeutics AG's strategy appears more focused on cost efficiency. This divergence highlights the strategic choices companies make in balancing growth with financial prudence, offering valuable insights for investors and industry analysts alike.